Core Insights - BeyondSpring Inc. reported Q3 2025 financial results and highlighted significant clinical and corporate milestones, particularly focusing on its lead asset, Plinabulin, which is in late-stage development for cancer treatment [1][2]. Clinical Developments - Plinabulin has shown a favorable safety profile and potential as an immune-modulating therapy, with over 700 patients treated. It demonstrated an 85% disease control rate in combination with docetaxel and Keytruda for metastatic non-small cell lung cancer (NSCLC) patients who progressed after PD-1/L1 inhibitors [2][4]. - The global Phase 3 DUBLIN-3 trial results published in The Lancet Respiratory Medicine indicated that Plinabulin combined with docetaxel achieved durable survival benefits and reduced chemotherapy-induced neutropenia [2][4]. - A Phase 2 study showed a median progression-free survival (PFS) of 7.0 months and a 12-month overall survival (OS) rate of 79% for patients treated with Plinabulin, docetaxel, and pembrolizumab [5]. Financial Performance - For the nine months ended September 2025, the net loss was $6.2 million, a decrease from $6.9 million for the same period in 2024. The net loss for Q3 2025 was $1.7 million, compared to $2.2 million in Q3 2024 [7][10]. - Research and development (R&D) expenses increased to $2.9 million for the nine months ended September 2025, up from $2.2 million in the same period in 2024, primarily due to higher drug manufacturing and regulatory affairs expenses [10][17]. - General and administrative (G&A) expenses decreased to $3.4 million for the nine months ended September 2025, down from $4.9 million in 2024, attributed to lower salary expenses and professional service costs [10][17]. Corporate Milestones - SEED Therapeutics, co-founded by BeyondSpring, completed a $30 million Series A-3 financing and received IND clearance from both the US FDA and China NMPA for its lead program targeting RBM39 [4][5]. - SEED was named a finalist for the 2025 Prix Galien USA "Best Start-Up" Award, highlighting its innovative approach in the field of targeted protein degradation [4][5].

Adoption & Endorsement - Top CEOs are choosing Grok AI for its versatility in daily life and decision-making [1] - Eli Lilly's CEO utilizes Grok AI [1] - NVIDIA CEO Jensen Huang employs Grok for artistic and creative endeavors [1] Key Features - Grok AI offers unlimited AI usage [1] - Grok AI is considered the most helpful AI for personal and business decisions [1]

coming in a big year for biopharma M&A, 15 deals worth $1 billion or more have been struck so far in 2025, as big pharma looks to replenish their pipeline, so can biotech keep the momentum going and how should investors approach the space. Right now, I don't know if a lot of people are aware about this performance of the sector versus the Mag-7 neck and neck. >> Well, if they'd be watching CNBC's Fast Money, they might be wearing Tim's the guy that gets the bandaid on his arm after he gets an inoculation.Ri ...

11/11/2025The Dow Jones hit a closing high while the broader market held recent gains. Palantir and Eli Lilly are in... 11/11/2025The Dow Jones hit a closing high while the broader... INVESTING RESOURCES BREAKING: Futures Rise After Dow Hits Record Close Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We apologize for any inconvenience. Dow Jones futures, along with S&P 500 futures and Nasdaq 100 futures, traded slightly higher ahead of T ...

Mergers & Acquisitions - The bidding war between Novo Nordisk and Pfizer for weight loss drug startup Met Sara has ended, with Novo Nordisk stepping aside [1] - Novo Nordisk withdrew its offer due to potential regulatory risks flagged by the FTC regarding the deal structure [1] - Pfizer intends to acquire Met Sara to enter the obesity business [3] Weight Loss Drug Market - The industry anticipates lower costs and greater availability of weight loss drugs in oral form within a year or two [4] Delivery Services - Instacart's futures are up 6-8%, indicating strong demand for grocery and restaurant delivery services [4][5] - Instacart generates approximately 29% of its revenue from non-delivery transactions, including grocery technology, subscriptions, and advertising sales [6] - Instacart introduced an AI-powered assistant for grocers to aid in purchasing decisions [6] Food Industry - Tyson Foods - Tyson Foods' shares decreased by as much as 15% [8] - Tyson Foods anticipates little change in results for the next year [8] - The beef segment is projected to experience an adjusted operating loss of $400 million to $600 million next year [8] - A cattle shortage is driving up prices for Tyson Foods [8] - The U S cattle herd is expected to begin rebuilding next year, but the benefits won't be seen before 2028 [9] - Higher demand for chicken is offsetting losses in the beef segment [9][10]

Group 1: Weight Loss Drug Market - The bidding war for Met Sara between Novo Nordisk and Pfizer has concluded, with Novo deciding not to raise its offer due to potential regulatory risks flagged by the FTC [1][2] - Pfizer has agreed to acquire Met Sara, indicating its interest in entering the obesity treatment market [3] Group 2: Grocery Delivery Services - Maple Bear reported better-than-expected growth in orders, reflecting strong demand for grocery and restaurant delivery services [5] - The company generates approximately 29% of its revenue from non-delivery transactions, including grocery technology and advertising sales [6] Group 3: Tyson Foods and Meat Industry - Tyson Foods anticipates an adjusted operating loss of $400 million to $600 million in its beef segment for the next year, compared to a loss of $426 million this year, driven by cattle shortages [8] - The U.S. cattle herd is expected to begin rebuilding next year, but benefits from this are not anticipated until 2028 [9] - Increased demand for chicken is helping to offset losses in the beef segment, as chicken represents the second-largest revenue portion for Tyson [10]

Core Insights - The third-quarter 2025 reporting cycle for the Medical sector, which includes pharma/biotech and medical device companies, is nearing completion [1] Earnings Performance - Major pharmaceutical companies like Amgen, Novo Nordisk, and Pfizer reported earnings, with Amgen and Pfizer showing strong results and raising their EPS outlook for 2025, while Novo Nordisk faced weaker-than-expected results and reduced its full-year guidance due to slower growth in its GLP-1 portfolio [2] - As of November 5, nearly 82% of companies in the Medical sector, representing 92% of the sector's market capitalization, reported quarterly earnings, with approximately 92% beating earnings estimates and around 84% exceeding revenue expectations. Year-over-year earnings rose over 4%, while revenues increased nearly 11%, with overall expected increases of 3.0% in earnings and 10.5% in sales compared to the previous year [3] Potential Earnings Surprises - Four biotech companies—Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma, and Immuneering—are highlighted as likely to deliver earnings beats based on their positive Earnings ESP and solid Zacks ranks [4][10] - Alto Neuroscience has an Earnings ESP of +16.41% and a Zacks Rank 2, with a consensus estimate for a loss of 66 cents per share [7] - Autolus Therapeutics has an Earnings ESP of +22.30% and a Zacks Rank 2, with a consensus estimate for a loss of 23 cents per share [11] - Ascendis Pharma has an Earnings ESP of +34.28% and a Zacks Rank 3, with a consensus estimate for a loss of 41 cents per share [13] - Immuneering has an Earnings ESP of +21.62% and a Zacks Rank 3, with a consensus estimate for a loss of 37 cents per share [15]

Core Insights - The article emphasizes the potential of investing in smaller, lesser-known biotech companies alongside established market leaders, highlighting Viking Therapeutics and Axsome Therapeutics as promising candidates for growth in the biotech sector [1][2]. Viking Therapeutics - The weight loss market is projected to grow from $15 billion last year to $150 billion by 2035, driven by breakthroughs and increasing demand for obesity-related treatments [3]. - Viking Therapeutics is developing VK2735, a dual GLP-1/GIP agonist, currently in phase 3 trials for subcutaneous use, with promising efficacy observed in mid-stage trials for an oral formulation [4]. - The company is also working on another weight-loss candidate in preclinical studies and plans to initiate human clinical trials next year, alongside VK2809, which has completed phase 2 studies for metabolic dysfunction-associated steatohepatitis [7]. Axsome Therapeutics - Axsome Therapeutics has achieved significant clinical and regulatory advancements, with third-quarter revenue reaching $171 million, a 63% year-over-year increase, primarily due to its depression medication, Auvelity [9]. - Auvelity, launched in 2022, is expected to achieve blockbuster status in treating depression and is awaiting approval for use in Alzheimer's disease agitation, with potential peak sales estimated between $1.5 billion to $3 billion [10][11]. - The company has a robust pipeline with other approved products and ongoing late-stage trials, including AXS-12 for narcolepsy and AXS-14 for fibromyalgia, which are expected to enhance financial performance [12][13].

Core Insights - Organon is set to announce its earnings results, with analysts expecting flat revenue year on year at $1.57 billion, a slowdown from the previous year's 4.1% increase [2] - Last quarter, Organon reported revenues of $1.59 billion, exceeding analysts' expectations by 2.8% and achieving a strong performance in terms of both revenue and EPS estimates [1][3] Revenue Expectations - Analysts have generally maintained their revenue estimates for Organon over the past 30 days, indicating a stable outlook heading into earnings [3] - The company has missed Wall Street's revenue estimates twice in the last two years, raising concerns about its performance consistency [3] Peer Performance - In the branded pharmaceuticals segment, peers like Eli Lilly and Collegium Pharmaceutical reported significant year-on-year revenue growth of 53.9% and 31.4%, respectively, both exceeding analysts' expectations [4] - Positive sentiment in the branded pharmaceuticals sector is reflected in an average share price increase of 3.9% over the last month, contrasting with Organon's decline of 29.4% during the same period [5] Analyst Sentiment - The average analyst price target for Organon is $10.83, while its current share price stands at $6.78, indicating potential upside if the company can meet or exceed expectations [5]

>> IT IS 10:00 A.M. IN LONDON AND 5:00 A.M. IN NEW YORK CITY. LET US GET STARTED WITH WHAT YOU NEED TO KNOW. A TERRIBLE WEEK FOR TECH. VALUATION WORRIES KNOCKING GLOBAL EQUITIES. MID-CAP STOCKS SELLOFF DESPITE POCKETS OF POSITIVE EARNINGS REPORTS. THE TESLA TRILLIONAIRE. SHAREHOLDERS APPROVE A ONE TRILLION DOLLAR COMPENSATION PACKAGE TO ELON MUSK MARKING THE LARGEST PAYOFF EVER AWARDED TO A CEO. AIRLINES BEGIN CANCELING FLIGHTS AS THE GOVERNMENT SHUTDOWN DRAGS ON. WE ARE LIVE ON THE GROUND. LET US GET A QUI ...